維泰凱20毫克/毫升口服溶液

Țară: Taiwan

Limbă: chineză

Sursă: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

Ingredient activ:

Larotrectinib

Disponibil de la:

台灣拜耳股份有限公司 台北市信義區信義路5段7號53樓 (23167184)

Codul ATC:

L01EX12

Forma farmaceutică:

口服液劑

Compoziție:

主成分 (mg/mL) ; Larotrectinib (1013007500) (LAROTRECTINIB SULFATE…………………. ….24.600 mg g)MG

Unități în pachet:

玻璃瓶裝;;盒裝

Clasă:

製　劑

Tip de prescriptie medicala:

須由醫師處方使用

Produs de:

PENN PHARMACEUTICAL SERVICES LIMITED UNITS 23-24, TAFARNAUBACH INDUSTRIAL ESTATE, TAFARNAUBACH, TREDEGAR NP22 3AA, U.K. GB

Zonă Terapeutică:

larotrectinib

Indicații terapeutice:

適用於有NTRK 基因融合的實體腫瘤之成人和兒童病人，並應符合以下三項條件:1、具NTRK基因融合且無已知的後天阻抗性突變(acquired resistance mutation)；2、為轉移性實體腫瘤，或手術切除極可能造成嚴重病症(severe morbidity)；3、沒有合適的替代治療選項，或於治療後發生疾病惡化。

Rezumat produs:

有效日期: 2024/12/03; 英文品名: VITRAKVI 20mg/ml oral solution

Data de autorizare:

2019-12-03

Prospect

C